drugset / Trial / NCT01613677
Phase II, Open Label, Non-randomized, Trial of BKM120 for Metastatic or Locally Advanced Cervical Cancer
RandomizedSingle-groupOpen-labelTreatment
Summary
This is a single arm open label phase II trial to evaluate the oral daily use of BKM 120 in patients with recurrent unresectable or metastatic cervical cancer after palliative cisplatin based regimen failure. A complete treatment cycle is defined as a 28 days period.
Timeline
- Start
- 2015-11
- Primary completion
- 2017-09
- Completion
- 2017-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Buparlisib | Small molecule | — | Oral |
Indications
No indication recorded.